Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

This is the highest reported objective response rate of any systemic treatment in unresectable hepatocellular carcinoma, surpassing atezolizumab–bevacizumab (30%) 11 and STRIDE (20%). 13 However, this ...

as a first-line therapy for unresectable hepatocellular carcinoma (HCC) – the most common form of liver cancer – by 21st April next year. Approval would make an Opdivo regimen an option for ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

PD-1 blocking antibody and CTLA-4 blocking antibody As first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma Opdivo + Yervoy Approved as First-Line Tx for HCC ...

Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...